Abstract
Glial cells have increasingly been implicated as active participants in the pathogenesis of neurological diseases, but critical pathways and mechanisms controlling glial function and secondary non-cell autonomous neuronal injury remain incompletely defined. Here we use models of Alexander disease, a severe brain disorder caused by gain-of-function mutations in GFAP, to demonstrate that misregulation of GFAP leads to activation of a mechanosensitive signaling cascade characterized by activation of the Hippo pathway and consequent increased expression of A-type lamin. Importantly, we use genetics to verify a functional role for dysregulated mechanotransduction signaling in promoting behavioral abnormalities and non-cell autonomous neurodegeneration. Further, we take cell biological and biophysical approaches to suggest that brain tissue stiffness is increased in Alexander disease. Our findings implicate altered mechanotransduction signaling as a key pathological cascade driving neuronal dysfunction and neurodegeneration in Alexander disease, and possibly also in other brain disorders characterized by gliosis.
Introduction
Alexander disease (AxD) is a rare and devastating neurological disorder caused by gain-of-function mutations in GFAP (glial fibrillary acidic protein), the primary intermediate filament in astrocytes. While the hallmark of the disease is the accumulation of GFAP aggregates called Rosenthal fibers, it has remained unclear how these glial-specific changes lead to the widespread neuronal dysfunction and death seen in patients. This study, published in Nature Communications, provides evidence that AxD is a "mechanopathy," where altered cellular and tissue stiffness drives disease progression through a pathological mechanotransduction cascade.
Methods
The researchers employed a multi-model "fly-to-human" approach to identify the pathways linking GFAP mutations to neurodegeneration.
The study began with a genome-scale genetic screen in a Drosophila model of AxD, identifying 453 modifiers of GFAP toxicity. These modifiers were mapped to human homologs using DIOPT and analyzed via the Prize-collecting Steiner forest algorithm (PCSF) to construct a human protein-protein interaction network. To validate these findings biophysically, the team used rotational rheometry to measure brain tissue stiffness in AxD mouse models and developed 3D ex vivo cultures to observe the brain's response to varying mechanical environments. Finally, results were validated using human iPSC-derived astrocytes and postmortem brain tissue.
Key Insights: The Hippo-YAP-Lamin Axis
The computational network analysis identified a conserved mechanosensitive signaling cascade central to AxD pathology.
The core discovery is the Hippo-YAP-Lamin axis. Mutant GFAP leads to the stabilization of F-actin bundles via spectraplakin proteins. This actin reorganization inhibits the Hippo pathway, allowing the transcriptional coactivator YAP to enter the nucleus and upregulate A-type lamins. This signaling creates a "vicious cycle": mutant GFAP increases cellular rigidity, contributing to increased brain tissue stiffness, which in turn further activates mechanosensitive signaling in astrocytes.
Key Results
- Increased Tissue Rigidity: AxD mouse brains exhibited a significant ~28% increase in stiffness compared to wild-type controls (increasing from ~447 Pa to ~572 Pa).
- Molecular Upregulation: Nuclear YAP and Lamin A/C expression were markedly increased across human, mouse, fly, and iPSC models of the disease.
- Genetic Rescue: Reducing Lamin C expression in AxD flies significantly decreased seizure activity and rescued neuronal cell death, reducing it by nearly 50% in specific assays.
- Environmental Sensitivity: AxD fly brains were more sensitive to external stiffness; when cultured in stiff 3D collagen, they showed exaggerated upregulation of mechanosensitive markers.
Discussion and Future Directions
This study establishes that mechanical signaling is a primary driver of non-cell autonomous injury in AxD. By demonstrating that reducing mechanical signaling in astrocytes can rescue neurons, the authors highlight potential therapeutic targets. YAP inhibitors, currently under development for oncology, may offer a novel treatment path for AxD. Furthermore, the authors suggest this mechanosensitive cascade might be a general feature of reactive gliosis, potentially playing a role in more common disorders like Alzheimer’s or traumatic brain injury where GFAP is also highly upregulated.
Future work is needed to determine the exact temporal sequence of tissue stiffness versus cellular signaling in humans and to further characterize the biochemical changes in the extracellular matrix that contribute to increased rigidity.
Summary updated